Moderna beats on cost cuts, EU combo approval de-risks near-term

What happened

Moderna reported Q1 2026 revenue of $0.4B, in line with seasonal expectations, and a GAAP net loss of $(1.3)B, which includes a $0.9B non-recurring litigation charge. The company reiterated its 2026 outlook for up to 10% revenue growth and operating expense reductions, signaling confidence in its cost restructuring. Key regulatory milestones were achieved in the EU with approvals of mNEXSPIKE and mCOMBRIAX (COVID+flu combo), the latter being a central catalyst in our investment thesis. Moderna also initiated a Phase 3 study of intismeran autogene with Keytruda for high-risk NSCLC, expanding platform optionality beyond respiratory. Despite the headline loss, underlying operational progress aligns with our base case, and the EU approval of mCOMBRIAX de-risks near-term ex-US revenue contribution.

Implication

The EU approval of mCOMBRIAX converts a key regulatory catalyst from potential to realized, reducing uncertainty around 2026/27 respiratory season revenue. The $0.9B litigation charge is non-recurring and does not impair the cash runway. However, revenue concentration on COVID remains, and the U.S. flu PDUFA in August is still a binary event. We view risk/reward favorably at current levels given the balance sheet and catalyst timeline.

Thesis delta

The Q1 report confirms seasonal revenue and cost containment, but the standout is the EU approval of mCOMBRIAX, which shifts our thesis probability weight from regulatory risk to commercial execution in Europe. The Phase 3 oncology start adds longer-term optionality. This reduces downside risk in our base case and increases conviction in the 50% probability scenario.